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Hepatitis C virus infection has been identified as the major
cause of parenterally transmitted hepatitis [1]. Chronic hepatitis
C is a major problem in patients on maintenance hemodialysis
awaiting kidney transplantation [21. Whereas uremia seems to
predispose to chronic viral carrier status with little inflamma-
tory activity in the liver, the change in immune status after
kidney transplantation modified by immunosuppressive drugs
causes acceleration of inflammatory liver disease often leading
to death from liver failure [3].
For the first time an effective therapy became available with
the advent of interferon treatment for chronic hepatitis virus
infection. A bulk of evidence has accumulated during the last
decade showing that this therapy is of benefit in nonuremic
patients with chronic hepatitis C [4, 5]. However, little infor-
mation has been presented so far on chronically hepatitis C
virus-infected uremic patients treated with interferon. There-
fore, we conducted a study of interferon treatment in patients
on maintenance dialysis with regard to its efficacy in suppress-
ing viremia and tolerability of side effects.
We report the result of an open multicenter trial of interferon
treatment in patients on maintenance hemodialysis suffering
from chronic hepatitis C virus infection. The trial was con-
ducted by the Austrian Association of Nephrology.
Methods
Alter informed consent was obtained, the patients received 5
million IU interferon-a three times weekly given subcutane-
ously after hemodialysis for a four month period. This period of
time was chosen because of the evidence in the literature that
responders do indeed respond within the first two months of
treatment [6]. Thereafter the patients were followed further for
five months. A negative result was only accepted when PCR
remained negative in three independent tests.
All patients were known to be positive for anti-HCV (second
generation ELISA, Abbot Laboratories) for at least six months
and for HCV-RNA (tested before treatment commencement) as
shown in Table 1. Before entering and then every two weeks
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during treatment, RNA testing was done until two consecutive
evaluations were negative. Alter the end of treatment ( week
16), at week 18 and week 36, further RNA testing was carried
out. HCV-RNA was extracted from serum with the single-step
acid guanidium thiocyanate-phenol-chloroform method essen-
tially described by Chomczynski and Sacchi [7]. Sequences
specific for the 5'-non-coding region of HCV genome were
detected after reverse transcription of HCV-RNA and amplifi-
cation of cDNA with the nested PCR technique and confirma-
tion by Southern blot. Primers were designed according to
sequences published by Ulrich et alES]. PCR was run for 30
cycles for outers and inners each. A sensitivity limit of 1000 to
10,000 copies per ml serum was determined by amplification of
a diluted synthetic HCV-RNA standard. Precautions according
to Kwok and Higushi [9] were taken to avoid false positive
results. Each sample was tested at least twice. In addition, a
complete laboratory work-up was done at the same time.
Thirty-seven patients (15 women and 22 men; mean age 54
14 years) entered the trial. Time of dialysis treatment ranged
from three to 228 months (mean 84.16 64.03 months). For
renal diagnosis see Table 1. In the six-month pretrial period 23
patients had nonnal transaminases. Of 14 patients with initially
slightly elevated ALT levels (less than threefold the upper
normal limit), seven returned to normal ALT levels at the end of
therapy, three experienced a drop in ALT without reaching
normal levels and four had invariably elevated ALT values.
One patient of the 23 with normal pretherapeutic ALT levels
had elevated levels during and at the end of therapy, which
returned to normal after therapy had ended. None of the
patients showed evidence of advanced stage liver disease as
judged by clinical, laboratory, ultrasonographic or endoscopic
investigation. Generally, no correlation between ALT and
HCV-RNA was found.
Results
Twenty-three patients completed the study and 14 were
withdrawn for the following reasons: septicemia without preex-
isting leukocytopenia (N 3); grade III interferon toxicity (N =
6: fever, malaise, leukocytopenia, diarrhea or stupor); one
patient received a cadaveric kidney graft and had an uneventful
postoperative course. Four patients refused further therapy for
less severe IFN side-effects.
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Table 1. Patient characteristics and PCR results
HCV-PCR results
neg
Age Therapy Reasons for since week week
Sex years Nephrologic diagnosis week withdrawal pre week 16 ÷ 18 36
Therapy completed (N = 23)f 47 chronic GN 16 I + 2 — —
m 67 nephrosclerosis 16 I + 2 — —
m 70 chronic ON 16 I + 2 —
f 58 analgesic nephropathy 16 I + 2 —
m 49 reflux nephropathy 16 I + 2 — —
m 56 chronic ON 16 I + 2 — —
m 33 chronic UN 16 I + 2 — —
f 59 polycystic kidney disease 16 I 4- 2 — —f 67 polycystic kidney disease 16 I + 14 — —f 55 polycystic kidney disease 16 I + 2 — ()af 27 chronic GN 16 I + 2 — +
m 43 Alport syndrome 16 I + 2 — +
m 55 polycystic kidney disease 16 I 4- 6 — 4-
m 48 rapid progressive ON 16 I + 8 — +
m 33 chronic ON 16 I + 10 — +
m 61 nephrosclerosis 16 I + I + 4-f 68 chronic GN 16 I + I + +
m 65 rapid progressive GN 16 I + I -I- +
m 56 chronic GN 16 I + I + +
f 62 polycystic kidney disease 16 I + I + +
m 54 chronic ON 16 I + I + +
f 31 reflux nephropathy 16 I + I + +
m 46 diabetic nephropathy 16 I + I 4- +
Withdrawn from therapy (N = 14)f 29 chronic pylelonephritis 12 septicemia + 4 — —f 73 chronic ON 2 IFN toxicity + 2 — —
m 45 chronic GN 4 septicemia + 6 — +f 64 chronic pylelonephritis 9 septicemia + I + +f 81 polycystic kidney disease 5 IFN toxicity + I + +
m 54 nephrosclerosis 2 IFN toxicity + I + +
m 52 chronic GN 2 IFN toxicity + I + 4-
m 40 Alport syndrome 2 IFN toxicity + I 4- +
m 32 chronic ON 12 IFN toxicity + I + +f 25 chronic ON 1 Tx + I ND +
m 49 chronic ON 12 IFN toxicity 4- I ND +
m 64 chronic GN 10 IFN toxicity + I ND +f 72 analgesic nephropathy I IFN toxicity + I ND +
m 29 chronic ON 4 IFN toxicity + I ND ND
Abbreviations are: f, female; m, male; ON, glomerulonephritis; Tx, kidney transplantation; pre, before therapy; neg, negative; +, HCV-PCR
positive; —, HCV-PCR negative; nd, not done.
a Lost for follow-up after week 28.
During the entire treatment period 15 patients (41% of study
population or 65% of patients completing treatment) lost HCV-
RNA and remained negative until the end of treatment and two
weeks thereafter. Eleven were already negative after week 2;
the remaining four patients became negative after weeks 6, 8, 10
and 14, respectively. Eight of the 23 patients showed either no
response (N = 3) to interferon treatment or their HCV-RNA
results fluctuated during the time of observation. In the drop-
out group (N = 14) three further patients became sustained
negative for HCV-RNA after an average of four weeks of
therapy; two of them remained negative throughout the obser-
vation period. Elevated levels of transaminases fell during
treatment to normal levels; no flare-up of liver AST or ALT was
noticed. In the follow-up period of five months, five of the 15
responders relapsed. One patient was sustained negative until
week 28, when she was lost for follow-up (Table 1).
Discussion
Pathogenesis of chronic hepatitis virus infection in uremic
patients is still poorly understood. There is evidence to suggest
a complex immune defect [10, 11] in these patients. The
antiviral effect of interferon includes the induction of antiviral
proteins in infected cells and the enhancement of cellular
immune response by class I expression as well as a direct
immunostimulatory effect on effector lymphocytes. The ob-
served response rate of 65% of patients completing therapy
(41% of study population) and the relapse rate of 36% are
comparable to results in non-uremic patients [12]. This stresses
the importance of the direct antiviral effect of the drug in
immunocompromised patients.
The other noteworthy finding was the high rate of side effects
observed in the treated patients with a drop-out rate of 37%. Six
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patients experienced grade III IFN toxicity, but four patients
withdrew consent for further treatment because of less severe
side-effects; three patients were lost due to shunt septicemia, a
side-effect not usually encountered with JFN. This could be
caused by "priming" by the release of endogenous cytokines
induced by membrane contact of mononuclear cells during
dialysis treatment or to the chronic state of disease in these
patients.
On the basis of our experience IFN therapy seems to be
similarly efficacious in uremic and non-uremic patients, but side
effects seem to be more severe and less well tolerated.
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